EP Patent

EP2209775A1 — Heterobicyclic compounds as histamine h4-receptor antagonists

Assigned to UCB Pharma SA Belgium · Expires 2010-07-28 · 16y expired

What this patent protects

The present invention concerns heterobicyclic compounds of formula (I) processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

USPTO Abstract

The present invention concerns heterobicyclic compounds of formula (I) processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Drugs covered by this patent

Patent Metadata

Patent number
EP2209775A1
Jurisdiction
EP
Classification
—
Expires
2010-07-28
Drug substance claim
No
Drug product claim
No
Assignee
UCB Pharma SA Belgium
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.